TCL Archive An “insurgency” targets randomized trials, demands access to investigational drugs. August 5, 2005
TCL Archive Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules July 30, 1999
TCL Archive Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting April 29, 2011
TCL Archive In Brief: Chemical Carcinogenesis, Epidemiology Trail Viral Oncology In Budget Growth, Board Notes November 7, 1980
